{"id":"cyclophosphamide-and-azathioprine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression / leukopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea / vomiting"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is a nitrogen mustard alkylating agent that cross-links DNA and causes cell death, particularly affecting rapidly dividing cells including lymphocytes. Azathioprine is a prodrug converted to 6-mercaptopurine, which inhibits purine synthesis and reduces T and B cell proliferation. Together, they provide potent immunosuppression through complementary mechanisms.","oneSentence":"This combination uses cyclophosphamide as an alkylating agent and azathioprine as a purine antagonist to suppress immune cell proliferation and function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:16.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune diseases (likely vasculitis, lupus nephritis, or other systemic autoimmune conditions based on typical Phase 3 use)"}]},"trialDetails":[{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT05030155","phase":"PHASE3","title":"Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-30","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT06846255","phase":"PHASE4","title":"Comparing DCP and DAP for Pemphigus Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2021-06-15","conditions":"Pemphigus Vulgaris","enrollment":66},{"nctId":"NCT02954939","phase":"NA","title":"The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-03-01","conditions":"Lupus Nephritis","enrollment":50},{"nctId":"NCT05149768","phase":"PHASE2","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-02-14","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":"Wegener's Granulomatosis, Vasculitis","enrollment":84},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT03198689","phase":"PHASE2","title":"Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-07","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT03096275","phase":"PHASE3","title":"Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis","status":"COMPLETED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2017-03-16","conditions":"Takayasu Arteritis","enrollment":138},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT02444728","phase":"PHASE3","title":"Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE","status":"TERMINATED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2015-07","conditions":"Thrombocytopenia","enrollment":50},{"nctId":"NCT05207358","phase":"PHASE4","title":"Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"Institutul Clinic Fundeni","startDate":"2022-03-02","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT03770663","phase":"PHASE3","title":"Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-02-05","conditions":"Antisynthetase Syndrome (ASS), Interstitial Lung Disease","enrollment":76},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03468972","phase":"PHASE4","title":"Effect of Immunosuppression in IgA Nephropathy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-03","conditions":"Biopsy-proven IgA Nephropathy","enrollment":174},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT02294344","phase":"NA","title":"The Clinical Efficacy of DFPP in Patients With AAGN","status":"TERMINATED","sponsor":"Zhi-Hong Liu, M.D.","startDate":"2014-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":14},{"nctId":"NCT02728271","phase":"EARLY_PHASE1","title":"Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome","status":"TERMINATED","sponsor":"Mounzer Agha","startDate":"2016-04","conditions":"Churg-Strauss Syndrome","enrollment":1},{"nctId":"NCT00152113","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04","conditions":"Sickle Cell Disease","enrollment":5},{"nctId":"NCT00104299","phase":"PHASE2, PHASE3","title":"Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":197},{"nctId":"NCT02645565","phase":"PHASE4","title":"Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12","conditions":"Lupus Nephritis","enrollment":75},{"nctId":"NCT01275287","phase":"PHASE2","title":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-05","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":""},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT00774852","phase":"PHASE2","title":"Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Lupus Nephritis, Lupus Erythematosus, Systemic","enrollment":137},{"nctId":"NCT00554502","phase":"PHASE3","title":"Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2008-02","conditions":"IgA Nephropathy","enrollment":148},{"nctId":"NCT01446211","phase":"PHASE3","title":"Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis","status":"TERMINATED","sponsor":"Nordic Pharma SAS","startDate":"2011-11","conditions":"Wegeners Granulomatosis","enrollment":4},{"nctId":"NCT00425438","phase":"PHASE3","title":"A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Lupus Nephritis","enrollment":52},{"nctId":"NCT01858259","phase":"","title":"Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Gabriela Riemekasten","startDate":"2013-05","conditions":"Systemic Sclerosis, Interstitial Lung Diseases","enrollment":1372},{"nctId":"NCT01646385","phase":"","title":"Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":6393},{"nctId":"NCT02135380","phase":"PHASE1, PHASE2","title":"Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Kasiak Research Pvt. Ltd.","startDate":"2014-08","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00556192","phase":"PHASE2","title":"Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2006-06","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT00377637","phase":"PHASE3","title":"A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Lupus Nephritis","enrollment":370},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108},{"nctId":"NCT01207297","phase":"PHASE1","title":"Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2003-03","conditions":"SLE, Lupus Nephritis, Renal Insufficiency","enrollment":40},{"nctId":"NCT00615173","phase":"PHASE3","title":"Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2006-07","conditions":"Kidney Diseases, Lupus Nephritis, Tacrolimus","enrollment":81},{"nctId":"NCT00753103","phase":"PHASE2","title":"Anti-Cytokine Therapy for Vasculitis","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2003-01","conditions":"Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis","enrollment":37},{"nctId":"NCT00664599","phase":"PHASE2","title":"Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2006-04","conditions":"Behcet's Syndrome","enrollment":20},{"nctId":"NCT00349674","phase":"PHASE3","title":"WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1999-01","conditions":"Systemic Wegener's Granulomatosis","enrollment":126},{"nctId":"NCT00400075","phase":"PHASE4","title":"CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1996-07","conditions":"Polyarteritis Nodosa, Microscopic Polyangiitis","enrollment":124},{"nctId":"NCT00399399","phase":"PHASE4","title":"CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1996-07","conditions":"Churg-Strauss Syndrome","enrollment":72},{"nctId":"NCT00307645","phase":"PHASE3","title":"IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2003-05","conditions":"ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2577,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cyclophosphamide and azathioprine","genericName":"Cyclophosphamide and azathioprine","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses cyclophosphamide as an alkylating agent and azathioprine as a purine antagonist to suppress immune cell proliferation and function. Used for Autoimmune diseases (likely vasculitis, lupus nephritis, or other systemic autoimmune conditions based on typical Phase 3 use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}